Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 16 September 2008
European Journal of Endocrinology (2008) In press
DOI: 10.1530/EJE-08-0487
Copyright © 2008 by European Society of Endocrinology
This Article
Right arrow Accepted manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Alves, L.
Right arrow Articles by Azevedo, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alves, L.
Right arrow Articles by Azevedo, A.

CLINICAL STUDY

Hypercholesterolemia, eligibility for lipid lowering therapy and therapeutic success - population-based study in a Portuguese urban population

Luis Alves and Ana Azevedo

L Alves, Department of Hygiene and Epidemiology, University of Porto Medical School; Institute of Public Health - University of Porto (ISPUP), Porto, Portugal
A Azevedo, Department of Hygiene and Epidemiology, University of Porto Medical School; Institute of Public Health - University of Porto (ISPUP), Porto, Portugal

Correspondence: Luis Alves, Email: luisaaalves{at}gmail.com

Abstract

Background: We aimed to estimate (1) the prevalence of hypercholesterolemia, (2) the proportion of individuals eligible for treatment with lipid-lowering drugs, and (3) therapeutic success, according to the European guidelines on cardiovascular disease prevention in clinical practice.

Design: Population-based cross-sectional study.

Methods: We surveyed a representative sample of the population of Porto aged 40-65 years. Trained interviewers collected data from 1215 subjects (789 women) on demographic variables, medical history and medication using structured questionnaires. A fasting venous blood sample was withdrawn. Subjects were considered low-risk or high-risk as indicated in the European guidelines. Hypercholesterolemia was defined as total cholesterol (TC) ≥5mmol/L or LDL-cholesterol (LDL-C) ≥3mmol/L in low-risk subjects, TC ≥4.5mmol/L or LDL-C ≥2.5mmol/L in high-risk subjects or being medicated with lipid lowering drugs. Eligibility for treatment was defined as being high-risk and having TC ≥4.5mmol/L, LDL-C ≥2.5mmol/L or being on treatment. We defined therapeutic success as having TC <4.5mmol/L and LDL-C <2.5mmol/L among medicated subjects.

Results: Overall, 84.9% (95% confidence interval (95% CI): 82.7-86.8) of subjects had hypercholesterolemia and 9.1% (95% CI: 7.5-10.8) were medicated with lipid-lowering drugs. Men were more likely to be eligible for treatment (42.4%) than women (22.4%) (OR=2.69, 95%CI 2.07-3.52). Therapeutic success was less frequent in men (46.8%) than in women (66.7%), (OR=0.39, 95% CI 0.17-0.87).

Conclusion: Strict interpretation of the European guidelines would label 85% of the general population in this age group as hypercholesterolemic and a third eligible for drug treatment. Questions arise regarding medicalization, resource allocation and sustainability within the healthcare system.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 European Society of Endocrinology.